Claims for Patent: 9,260,494

Summary for Patent: 9,260,494

Title:	Biological active proteins having increased in vivo and/or in vitro stability
Abstract:	Increased in vivo and/or in vitro stability is imparted to a biologically active protein by fusing to an amino acid sequence consisting of at least about 100 amino acid residues, which consist essentially of Alanine, Serine and Proline, which form a random coil conformation. Specific examples are described. Also described are related nucleic acids, vectors and cells encoding such amino acids; compositions of biologically active proteins fused to a random coil domain, and methods of making and using the compounds and compositions of the invention.
Inventor(s):	Skerra; Arne (Freising, DE), Theobald; Ina (Landshut, DE), Schlapschy; Martin (Freising, DE)
Assignee:	Technische Universitat Munchen (Munich, DE)
Application Number:	13/963,953
Patent Claims:	1. A biologically active protein comprising (a) a first domain comprising an amino acid sequence having said biological activity; and (b) a second domain consisting of at least 80 amino acid residues which consists essentially of alanine, serine and proline residues and which forms a random coil conformation which mediates an increased in vivo and/or in vitro stability of said biologically active protein compared with the biologically active protein lacking said second domain. 2. The biologically active protein according to claim 1, wherein said second domain consists of no more than 10% of residues other than alanine, serine and proline. 3. The biologically active protein according to claim 1, wherein said second domain comprises a plurality of amino acid repeats consisting of Ala, Ser, and Pro residues and wherein no more than 6 consecutive amino acid residues are the same amino acid. 4. The biologically active protein according to claim 1, wherein said proline residues consist of 4% to 40% of said second domain. 5. The biologically active protein according to claim 1 wherein said second domain comprises the amino acid sequence selected from the group consisting of TABLE-US-00012 (SEQ ID NO: 18) ASPAAPAPASPAAPAPSAPA; (SEQ ID NO: 20) AAPASPAPAAPSAPAPAAPS; (SEQ ID NO: 22) APSSPSPSAPSSPSPASPSS; (SEQ ID NO: 63) SAPSSPSPSAPSSPSPASPS; (SEQ ID NO: 24) SSPSAPSPSSPASPSPSSPA; (SEQ ID NO: 26) AASPAAPSAPPAAASPAAPSAPPA; and (SEQ ID NO: 28) ASAAAPAAASAAASAPSAAA. 6. The biologically active protein according to claim 1, wherein said second domain consists of about 100 to 3000 amino acid residues. 7. The biologically active protein according to claim 1, wherein said first domain is selected from the group consisting of binding molecules, antibody fragments, cytokines, growth factors, hormones and enzymes. 8. The biologically active protein according to claim 7, wherein said binding molecule is selected from the group consisting of antibodies, Fab fragments, F(ab').sub.2 fragments, CDR derived peptidomimetics, single chain variable fragments (saFv), lectins and lipocalins. 9. The biologically active protein according to claim 1, wherein said first domain comprising an amino acid sequence having biological activity is selected from the group consisting of granulocyte colony stimulating factor, human growth hormone, alpha-interferon, beta-interferon, gamma-interferon, tumor necrosis factor, erythropoietin, coagulation factor VIII, gp120/gp160, soluble tumor necrosis factor I and II receptor, reteplase, exendin-4, anakinra, interleukin-2, and neutrophil gelatinase-associated lipocalin. 10. The biologically active protein according to claim 1, wherein said increased in vivo stability of said biologically active protein is a prolonged plasma half-life of said biologically active protein. 11. A composition comprising the biologically active protein according to claim 1. 12. The composition according to claim 11 which is a pharmaceutical composition, optionally further comprising a pharmaceutical acceptable carrier. 13. A nucleic acid molecule encoding the biologically active protein of claim 1. 14. A vector comprising the nucleic acid of claim 13. 15. A cell comprising the nucleic acid according to claim 13. 16. A method for the preparation of the biologically active protein according to claim 1 comprising culturing a cell comprising (a) a nucleic acid molecule encoding the biologically active protein of claim 1 or (b) a vector comprising a nucleic acid molecule encoding the biologically active protein of claim 1 and isolating said biologically active protein from the culture. 17. A method of treating hormone deficiency-related disorders, auto-immune disease, cancer, anaemia, neovascular diseases, infectious/inflammatory diseases, thrombosis, myocardial infarction, diabetes, and reperfusion injury or other kidney diseases in a subject, comprising administration to the subject (a) the biologically active protein of claim 1; (b) a nucleic acid encoding the biologically active protein of claim 1; (c) a vector comprising a nucleic acid and encoding the biologically active protein of claim 1; (d) a cell comprising a nucleic acid molecule encoding the biologically active protein of claim 1; or (e) a cell comprising a vector comprising a nucleic acid molecule encoding the biologically active protein of claim 1. 18. A kit comprising (a) the biologically active protein of claim 1; (b) a nucleic acid encoding the biologically active protein of claim 1; (c) a vector comprising a nucleic acid and encoding the biologically active protein of claim 1; (d) a cell comprising a nucleic acid molecule encoding the biologically active protein of claim 1; or (e) a cell comprising a vector comprising a nucleic acid molecule encoding the biologically active protein of claim 1. 19. The biologically active protein of claim 2, wherein said second domain consists of no more than 5% of residues other than alanine, serine and proline. 20. The biologically active protein of claim 19, wherein said second domain consists of no more than 2% of residues other than alanine, serine and proline. 21. The biologically active protein of claim 19, wherein said residues other than alanine, serine and proline are selected from the group consisting of Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Val.

Details for Patent 9,260,494

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Chiesi Usa, Inc.	RETAVASE	reteplase	For Injection	103786	10/30/1996		2027-06-21
Swedish Orphan Biovitrum Ab (publ)	KINERET	anakinra	Injection	103950	11/14/2001		2027-06-21